These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 29958605

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O.
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
    Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ, van Grotel M, van den Heuvel-Eibrink MM, DCOG-LATER, The Netherlands.
    Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL.
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The incidence of hearing impairment after successful treatment of neuroblastoma.
    Simon T, Hero B, Dupuis W, Selle B, Berthold F.
    Klin Padiatr; 2002 Feb; 214(4):149-52. PubMed ID: 12165893
    [Abstract] [Full Text] [Related]

  • 10. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.
    Waissbluth S, Peleva E, Daniel SJ.
    Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1187-1196. PubMed ID: 27245751
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cisplatinum ototoxicity in children, long-term follow up.
    Al-Khatib T, Cohen N, Carret AS, Daniel S.
    Int J Pediatr Otorhinolaryngol; 2010 Aug; 74(8):913-9. PubMed ID: 20846503
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
    Knight KR, Kraemer DF, Neuwelt EA.
    J Clin Oncol; 2005 Dec 01; 23(34):8588-96. PubMed ID: 16314621
    [Abstract] [Full Text] [Related]

  • 16. Audiological Monitoring in Children Treated with Platinum Chemotherapy.
    Fetoni AR, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G, Paludetti G.
    Audiol Neurootol; 2016 Dec 01; 21(4):203-211. PubMed ID: 27286730
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
    Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ.
    J Pediatr Hematol Oncol; 2008 Feb 01; 30(2):130-4. PubMed ID: 18376265
    [Abstract] [Full Text] [Related]

  • 19. Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors.
    Gupta AA, Capra M, Papaioannou V, Hall G, Maze R, Dix D, Weitzman S.
    J Pediatr Hematol Oncol; 2006 Feb 01; 28(2):91-4. PubMed ID: 16462581
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.